ArticleScientific reports2025
Silver and polystyrene nanoparticles activate oestrogen signalling via cytoplasmic oestrogen receptor.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
This study explores the endocrine-disrupting potential of two commonly encountered nanomaterials, nanoplastic and silver nanoparticles (AgNPs). Many environmental pollutants, especially endocrine-disrupting chemicals (EDCs), such as bisphenol, heavy metals, interfere with hormone function, posing a serious risk for public health, e.g. prevalence of breast cancer, whose incidence correlates strongly with EDC exposure. However, the impact on hormonal homeostasis of many environmental contaminants, such as nanoplastic, is still unknown. Nanoplastic is a product of the weathering process of plastic goods, while AgNPs are released to the environment from everyday use items, such as health care products, food-related materials or medical devices. These nanoparticles penetrate biological barriers, accumulate in tissues, and may affect oestrogen signalling. Thus, this study investigated how AgNPs and nanopolystyrene (PSNPs) interact with oestrogen receptor (ESR1) signalling in breast cancer cells. The study revealed that in ESR1-positive (ER+) cells, AgNPs notably enhanced ESR1-mediated cell proliferation and progression through the S-phase of the cell cycle, particularly in oestrogen-deprived conditions. The observed effect was ESR1-dependent and effectively blocked by tamoxifen, revealing a ligand-independent activation mechanism. AgNPs downregulated ESR1 signalling-dependent genes, which are linked to cell cycle and proliferation pathways (e.g., IRS1, NCOR1, MED1). PSNPs showed a similar, but milder effect, stimulating ESR1 activation only in the presence of oestrogen (E2). Simultaneous treatment with AgNPs and PSNPs induced a distinct effect, namely, reduced CITED2 and BDNF expression, which was highly dependent on E2 status. The presence of PSNPs also mitigated AgNPs-induced reduction of BRCA1 expression. This study highlights how nanomaterial-induced ESR1 activation can lead to enhanced epithelial-mesenchymal transition and cell cycle progression, suggesting potential adverse effects of nanomaterials in ER+ cancer proliferation via protein kinase-mediated ESR1 modulation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.